Do I need a prescription for Perphenazine 2mg tablets?

Perphenazine 2mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Perphenazine 2mg tablets?

Perphenazine 2mg tablets is the generic name. It is available under brand names including: Fentazin 2mg tablets, Perphenazine 2mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Perphenazine 2mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

2mg

Oral

Antipsychotic

An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.

Active ingredients:

Perphenazine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.02.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N05AB03

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antipsychotic

Check interactions for Perphenazine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Perphenazine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Perphenazine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Perphenazine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

2 branded products available

2 productsShow details

2 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Perphenazine on the MHRA register

Perphenazine 2mg tablets

Special Order

None

Special

Fentazin 2mg tablets

Advanz Pharma

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

30 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Trifluoperazine 1mg/5ml oral suspension

Oral suspension

1mg/5ml

Same therapeutic group

Perphenazine 2mg/5ml oral suspension

Oral suspension

2mg/5ml

Same therapeutic group

Perphenazine 4mg/5ml oral suspension

Oral suspension

4mg/5ml

Same therapeutic group

Fluphenazine 2.5mg tablets

Tablet

2.5mg

Same therapeutic group

Fluphenazine 5mg tablets

Tablet

5mg

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Perphenazine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Perphenazine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42277011000001104

dm+d ID

42277011000001104

VTM (Virtual Therapeutic Moiety)

777146003

VMP (Virtual Medicinal Product)

42277011000001104

BNF code

04020100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N05AB03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

48 found

Half-life

8-12 hours

Mechanism

Binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity.

Food interactions

1 warning

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

40%

Absolute bioavailability is 40% following oral administration.

Half-life

8-12 hours

8-12 hours, but ranges up to 20 hours.

Metabolism

Hepatic.

Elimination

Perphenazine is extensively metabolized in the liver to a number of metabolites by sulfoxidation, hydroxylation, dealkylation, and glucuronidation.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.

Properties:

solid

Avg. mass: 403.97 Da

View FDA drug label

DrugBank indication

For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.

Also known as(86)

2-(4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol

2-chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine

4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol

4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazineethanol

Chlorpiprazine

Etaperazin

Etaperazine

Ethaperazine

Dosage forms(44)

Syrup (Oral)

Tablet, film coated (Oral) — 4 mg

Tablet, film coated (Oral) — 8 mg

Solution (Parenteral) — 5.000 mg

Tablet (Oral) — 4.000 mg

Solution (Parenteral) — 5 mg

Tablet (Oral) — 16 mg

Tablet (Oral) — 16 mg/1

Molecular properties(19)

Drug interactions(1220)

Known interactions with other medications. Always consult a healthcare professional.

Deferasirox

Unknown severity

DB01609

The serum concentration of Perphenazine can be increased when it is combined with Deferasirox.

Check this interaction

Peginterferon alfa-2b

Unknown severity

DB00022

The serum concentration of Perphenazine can be increased when it is combined with Peginterferon alfa-2b.

Check this interaction

Leflunomide

Unknown severity

DB01097

The serum concentration of Perphenazine can be decreased when it is combined with Leflunomide.

Check this interaction

Teriflunomide

Unknown severity

DB08880

The serum concentration of Perphenazine can be decreased when it is combined with Teriflunomide.

Check this interaction

Buprenorphine

Moderate

DB00921

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.

Check this interaction

Hydrocodone

Moderate

DB00956

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Perphenazine can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.

Check this interaction

Mirtazapine

Moderate

DB00370

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.

Check this interaction

Orphenadrine

Moderate

DB01173

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.

Check this interaction

Rotigotine

Moderate

DB05271

Perphenazine may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Perphenazine.

Check this interaction

Sodium oxybate

Moderate

DB09072

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.

Check this interaction

Thalidomide

Moderate

DB01041

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Amisulpride

Moderate

DB06288

Perphenazine may increase the antipsychotic activities of Amisulpride.

Check this interaction

Methylphenidate

Unknown severity

DB00422

The risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate.

Check this interaction

Dexmethylphenidate

Unknown severity

DB06701

The risk or severity of adverse effects can be increased when Perphenazine is combined with Dexmethylphenidate.

Check this interaction

Metoclopramide

Unknown severity

DB01233

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Perphenazine.

Check this interaction

Quinagolide

Moderate

DB09097

The therapeutic efficacy of Quinagolide can be decreased when used in combination with Perphenazine.

Check this interaction

Sulpiride

Moderate

DB00391

Perphenazine may increase the antipsychotic activities of Sulpiride.

Check this interaction

Methadone

Unknown severity

DB00333

The risk or severity of adverse effects can be increased when Methadone is combined with Perphenazine.

Check this interaction

Lithium citrate

Moderate

DB14507

Lithium citrate may increase the neurotoxic activities of Perphenazine.

Check this interaction

Lithium hydroxide

Moderate

DB14506

Lithium hydroxide may increase the neurotoxic activities of Perphenazine.

Check this interaction

Mequitazine

Moderate

DB01071

Perphenazine may increase the arrhythmogenic activities of Mequitazine.

Check this interaction

Thiopental

Unknown severity

DB00599

The risk or severity of adverse effects can be increased when Perphenazine is combined with Thiopental.

Check this interaction

Atomoxetine

Moderate

DB00289

The metabolism of Atomoxetine can be decreased when combined with Perphenazine.

Check this interaction

Metyrosine

Unknown severity

DB00765

The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with Perphenazine.

Check this interaction

Mirabegron

Unknown severity

DB08893

The serum concentration of Perphenazine can be increased when it is combined with Mirabegron.

Check this interaction

Abiraterone

Unknown severity

DB05812

The serum concentration of Perphenazine can be increased when it is combined with Abiraterone.

Check this interaction

Cyproterone acetate

Moderate

DB04839

The metabolism of Perphenazine can be increased when combined with Cyproterone acetate.

Check this interaction

Ethanol

Moderate

DB00898

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Azelastine

Moderate

DB00972

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Check this interaction

Brimonidine

Moderate

DB00484

Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.

Check this interaction

Zimelidine

Unknown severity

DB04832

The risk or severity of adverse effects can be increased when Perphenazine is combined with Zimelidine.

Check this interaction

Dapoxetine

Unknown severity

DB04884

The risk or severity of adverse effects can be increased when Perphenazine is combined with Dapoxetine.

Check this interaction

Seproxetine

Unknown severity

DB06731

The risk or severity of adverse effects can be increased when Perphenazine is combined with Seproxetine.

Check this interaction

Citalopram

Unknown severity

DB00215

The risk or severity of adverse effects can be increased when Perphenazine is combined with Citalopram.

Check this interaction

Trazodone

Unknown severity

DB00656

The risk or severity of adverse effects can be increased when Perphenazine is combined with Trazodone.

Check this interaction

Sertraline

Unknown severity

DB01104

The risk or severity of adverse effects can be increased when Perphenazine is combined with Sertraline.

Check this interaction

Showing 50 of 1220 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol. Consuming alcohol may increase hypotension. Perphenazine may increase the effects of alcohol.

Toxicity & overdose

Symptoms of overdose include stupor or coma, and children may have convulsive seizures. Signs of arousal may not occur for 48 hours. Oral LD₅₀=318 mg/kg (rat); IPR LD₅₀=64 mg/kg (mouse)

How it works

Mechanism of action

Binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone and vomiting centre. Perphenazine also binds the alpha andrenergic receptor. This receptor's action is mediated by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.

Pharmacodynamics

Perphenazine is a piperazinyl phenothiazine, acts on the central nervous system, and has a greater behavioral potency than other phenothiazine derivatives whose side chains do not contain a piperazine moiety. It is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Perphenazine is 10 to 15 times as potent as chlorpromazine; that means perphenazine is a highly potent antipsychotic. In equivalent doses it has approximately the same frequency and severity of early and late extrapypramidal side-effects compared to Haloperidol.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Absolute bioavailability is 40% following oral administration.

Half-life

8-12 hours, but ranges up to 20 hours.

Metabolism

Hepatic.

Route of elimination

Perphenazine is extensively metabolized in the liver to a number of metabolites by sulfoxidation, hydroxylation, dealkylation, and glucuronidation.

Drug targets(3)

Proteins and enzymes this drug interacts with in the body

D(2) dopamine receptor

BE0000756

DRD2

antagonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase .
PMID:21645528
Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)

D(1A) dopamine receptor

BE0000020

DRD1

antagonist

Specific functionarrestin family protein binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase

Calmodulin-3

BE0027477

CALM3

inhibitor

Specific functionadenylate cyclase activator activity

Cellular location

Cytoplasm, cytoskeleton, spindle

General function & pharmacology

Calmodulin acts as part of a calcium signal transduction pathway by mediating the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding .
PMID:16760425 PMID:31454269
Calcium-binding is required for the activation of calmodulin .
PMID:16760425 PMID:31454269 PMID:35568036

Among the enzymes to be stimulated by the calmodulin-calcium complex are a number of protein kinases, such as myosin light-chain kinases and calmodulin-dependent protein kinase type II (CaMK2), and phosphatases .
PMID:16760425 PMID:35568036
Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis PMID:16760425

Metabolizing enzymes(7)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP1A2Cytochrome P450 1A2

substrate

CYP2C18Cytochrome P450 2C18

substrate

CYP2C19Cytochrome P450 2C19

substrate

CYP2C8Cytochrome P450 2C8

substrate

CYP2C9Cytochrome P450 2C9

substrate

CYP3A4Cytochrome P450 3A4

substrate

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

Carriers(1)

Proteins that carry this drug through the body

Albumin

BE0000530

ALB

regulator

Specific functionantioxidant activity

Cellular location

Secreted

General function & pharmacology

Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc .
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).

Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).

Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017

ATC classification(1 code)

ATC N05AB03

Affected organisms(1)

Humans and other mammals

International brands(7)

Experimental properties(6)

External resources(3)

RxList PDRhealth Drugs.com

Commercial products(206)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Perphenazine

DB00850

CAS number

58-39-9

UNII (FDA)

FTA7XXY4EZ

InChI Key (molecular fingerprint)

RGCVKNLCSQQDEP-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

8003

ChEBI

8028

PubChem Compound

4748

PubChem Substance

46507058

KEGG Compound

C07427

KEGG Drug

D00503

ChemSpider

4586

BindingDB

50130273

PharmGKB

PA450882

Therapeutic Targets Database

DAP000100

IUPHAR

209

Guide to Pharmacology

209

Wikipedia

Perphenazine

ChEMBL

CHEMBL567

ZINC

ZINC000019228902

RxCUI

8076

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1442

GeneCards

CALM1

UniProtKB

P0DP23

UniProt Accession

CALM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1445

GeneCards

CALM2

UniProtKB

P0DP24

UniProt Accession

CALM2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1449

GeneCards

CALM3

UniProtKB

P0DP25

UniProt Accession

CALM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2620

GeneCards

CYP2C18

GenBank Gene Database

M61853

Guide to Pharmacology

1327

UniProtKB

P33260

UniProt Accession

CP2CI_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2622

GenAtlas

CYP2C8

GeneCards

CYP2C8

GenBank Gene Database

M17397

Guide to Pharmacology

1325

UniProtKB

P10632

UniProt Accession

CP2C8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:399

GenAtlas

ALB

GeneCards

ALB

GenBank Gene Database

V00494

GenBank Protein Database

28590

UniProtKB

P02768

UniProt Accession

ALBU_HUMAN

International reference pricing

8 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.07/tablet

To $1.73/tablet

Apo-Perphenazine 2 mg Tablet

$0.07/tablet

Apo-Perphenazine 4 mg Tablet

$0.08/tablet

Apo-Perphenazine 8 mg Tablet

$0.09/tablet

Apo-Perphenazine 16 mg Tablet

$0.13/tablet

Perphenazine 2 mg tablet

$0.77/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated about 1 month ago(4 Mar 2026)

Back to medicines

Perphenazine 2mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
11

Chemical identifiers

Perphenazine

Additional database identifiers

International reference pricing

DrugBank citations

Perphenazine 2mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science11

Chemical identifiers

Perphenazine

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
11